Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case

Understanding Prognostic Factors for Human Papillomavirus Vaccination: A Rural Community Case–Control Study

Published:2023-09-28 Issue:10 Volume:11 Page:1536
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Colomé-Ceballos Lara¹²^ORCID,Clua-Espuny Josep Lluís³⁴^ORCID,Ceballos-García Concepción⁵,Clua-Queralt Josep³,Pla-Farnós Maria Jesús⁶^ORCID,Fernández-Sáez José⁴⁷^ORCID

Affiliation:

1. Sexual and Reproductive Attention, SAP Terres de l’Ebre, Catalonian Health Institute, 43500 Catalonia, Spain

2. Gynaecology Department, Hospital Verge de la Cinta de Tortosa, Catalonian Health Institute, 43500 Catalonia, Spain

3. EAP Tortosa Est. Primary Care, SAP Terres de l’Ebre, Catalonian Health Institute, 43500 Catalonia, Spain

4. Unitat de Suport a la Recerca Terres de l’Ebre, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol), 43500 Tortosa, Spain

5. Santa Creu de Jesús Hospital, Salut Tortosa, 43590 Catalonia, Spain

6. Gynaecology Department, Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s/n, L’Hospitalet de Llobregat, 08907 Barcelona, Spain

7. Faculty of Nursing, Terres de l’Ebre Campus, Rovira i Virgili University, 43500 Tortosa, Spain

Abstract

HPV vaccination coverage rates can vary depending on several factors. The main objective of this study is to identify possible independent prognostic factors that have an impact on HPV vaccination in a rural community, specifically related to sexual and reproductive health. A case–control, retrospective, community-based study was carried out on women aged 15 to 40 in the primary health centers of Southern Catalonia’s Terres de l’Ebre region, Spain, from 1 January 2020 to 31 December 2022. A random sample of 520 women with an average age of 29.3 (SD 7.8) years old was included in the study. Independent prognostic factors: age OR 0.680 (95% CI: 0.635–0.729, p < 0.001), immigrant origin OR 0.215 (95% CI: 0.109–0.422, p < 0.001), and HPV PCR OR 7.402 (95% CI: 2.504–21.880, p < 0.001). The variables that showed a barrier effect for HPV vaccination were age (OR 0.680, 95% CI 0.635–0.729, p < 0.001), and immigrant origin (OR 0.215, 95% CI 0.109–0.422, p < 0.001). The variable that showed a facilitating effect for HPV vaccination was HPV PCR (OR 7.402, 95% CI 2.504–21.880, p < 0.001).

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/10/1536/pdf

Reference69 articles.

1. World Health Organization (2023, January 23). Cervical Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.

2. World Health Organization (2023, June 25). Reaching 2030 Cervical Cancer Elimination Targets—New WHO Recommendations for Screening and Treatment of Cervical Pre-Cancer. Available online: https://www.who.int/news-room/events/detail/2021/07/06/default-calendar/reaching-2030-cervical-cancer-elimination-targets.

3. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019;Bruni;Prev. Med.,2021

4. Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries—The ADVANCE project;Braeye;Vaccine,2020

5. (2023, April 18). El Proceso de Vaciado de la España Interior No se Detiene, Advierten los Expertos. Available online: https://www.elperiodicodearagon.com/sociedad/2023/01/09/proceso-vaciado-espana-interior-detiene-80864275.html.